Skip to main content

Table 3 Characteristics of the 77 RA patients stratified by TGF-β 869C/T SNPs at baseline (T0) and after three months (T3) and six months (T6) of anti-TNF therapya

From: Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis

Characteristics

T0

T3

T6

P value

Mean age, years (± SD)

55.9 ± 14.3

57.1 ± 13.9

56.7 ± 14.1

NS

Mean disease duration, months (± SD)

118.8 ± 93.6

116.4 ± 94.8

118.8 ± 94.8

NS

RF-positive, n (%)

18 (78.2)

29 (85.2)

14 (70)

NS

ACPA-positive, n (%)

16 (69.5)

28 (82.3)

14 (70)

NS

Mean DAS28 (± SD)

5.3 ± 1.1

5.2 ± 1.1

4.8 ± 1.2

NS

Mean HAQ score (± SD)

1.2 ± 0.7

1.34 ± 0.8

1.28 ± 0.8

NS

Mean overall patient TES (± SD)

34.1 ± 22.1

34.7 ± 24.4

29.5 ± 16.8

NS

Mean MCP TES (± SD)

14.7 ± 8.8

12.6 ± 8.6

12.4 ± 6.2

NS

Mean PIP TES (± SD)

8 ± 7.1

10.3 ± 8.9

10.6 ± 7.8

NS

Mean MTP TES (± SD)

11.3 ± 9

11.7 ± 7.8

6.3 ± 5.7

*P

  1. aACPA: anticitrullinated protein/peptide antibody; DAS28: disease activity score in 28 joints; HAQ: Health Assessment Questionnaire; MCP: metacarpophalangeal; MTP: metatarsophalangeal; PIP: proximal interphalangeal; RA: rheumatoid arthritis; RF: rheumatoid factor; TES: total erosion score; TGF-β: transforming growth factor β. *P < 0.05, CC vs. TT; P = 0.01, CT vs. TT.